Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion
Neurocrine Biosciences is set to acquire Soleno Therapeutics for $2.9 billion, enhancing its portfolio with a treatment for a rare disease associated with insatiable hunger.
Neurocrine Biosciences has announced its acquisition of Soleno Therapeutics for a total consideration of $2.9 billion. This strategic move is aimed at expanding Neurocrine's therapeutic offerings.
Soleno Therapeutics brings to the table an approved medication targeting a rare disease characterized by insatiable hunger. This condition presents unique challenges in treatment and management.
The acquisition reflects a growing trend in the biotechnology sector where companies seek to enhance their capabilities through targeted acquisitions, particularly in niche therapeutic areas.